| Year |
Citation |
Score |
| 2023 |
Gunawan F, Ajaz S, Meneghini L, Gunasekaran U. Benefits of Electronic Consultations in Improving Diabetes Care Within a Safety-Net Health System. Clinical Diabetes : a Publication of the American Diabetes Association. 41: 292-295. PMID 37092146 DOI: 10.2337/cd22-0078 |
0.49 |
|
| 2021 |
Powell RE, Zaccardi F, Beebe C, Chen XM, Crawford A, Cuddeback J, Gabbay RA, Kissela L, Litchman ML, Mehta R, Meneghini L, Pantalone KM, Rajpathak S, Scribner P, Skelley JW, et al. Strategies for overcoming therapeutic inertia in type 2 diabetes: A systematic review and meta-analysis. Diabetes, Obesity & Metabolism. PMID 34180129 DOI: 10.1111/dom.14455 |
0.358 |
|
| 2021 |
Smith-Morris C, Rodriguez S, Soto R, Spencer M, Meneghini L. Decolonizing Care at Diagnosis: Culture, History, and Family at an Urban Inter-tribal Clinic. Medical Anthropology Quarterly. PMID 33998047 DOI: 10.1111/maq.12645 |
0.309 |
|
| 2021 |
Wees I, Gunasekaran U, Meneghini L. Optimizing Glucose Meter Downloads at Parkland Diabetes Clinic. Clinical Diabetes : a Publication of the American Diabetes Association. 39: 199-202. PMID 33986573 DOI: 10.2337/cd20-0056 |
0.486 |
|
| 2021 |
Chatha KK, Walsh B, La Fontaine J, Bowen ME, Meneghini L. Lower-Extremity Amputation Trends Among People With Diabetes in a Large Urban Environment. Diabetes Care. 44: e91-e92. PMID 33824141 DOI: 10.2337/dc20-2491 |
0.432 |
|
| 2020 |
Morales-Marroquin E, Xie L, Meneghini L, de la Cruz-Muñoz N, Almandoz JP, Mathew SM, Schneider BE, Messiah SE. Type 2 Diabetes and HbA1c Predict All-Cause Post-Metabolic and Bariatric Surgery Hospital Readmission. Obesity (Silver Spring, Md.). PMID 33215855 DOI: 10.1002/oby.23044 |
0.303 |
|
| 2020 |
Alvarez K, Townsend C, McNulty JN, Kubik M, Gunasekaran U, Ahmed F, Rodriguez K, Moran B, McManus J, Meneghini LF. Design and Implementation of an Electronic Tool to Measure Medication Adherence at the Point of Care. Clinical Diabetes : a Publication of the American Diabetes Association. 38: 382-385. PMID 33132508 DOI: 10.2337/cd20-0011 |
0.421 |
|
| 2020 |
Gabbay RA, Kendall D, Beebe C, Cuddeback J, Hobbs T, Khan ND, Leal S, Miller E, Novak LM, Rajpathak SN, Scribner P, Meneghini L, Khunti K. Addressing Therapeutic Inertia in 2020 and Beyond: A 3-Year Initiative of the American Diabetes Association. Clinical Diabetes : a Publication of the American Diabetes Association. 38: 371-381. PMID 33132507 DOI: 10.2337/cd20-0053 |
0.38 |
|
| 2020 |
Shao H, Fonseca V, Furman R, Meneghini L, Shi L. Impact of Quality Improvement (QI) Program on 5-Year Risk of Diabetes-Related Complications: A Simulation Study. Diabetes Care. PMID 32887705 DOI: 10.2337/Dc20-0465 |
0.352 |
|
| 2020 |
Meneghini L, Blonde L, Gill J, Dauchy A, Bacevicius A, Strong J, Bailey TS. Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomised, pragmatic real-life clinical trial. Diabetes, Obesity & Metabolism. PMID 32538550 DOI: 10.1111/dom.14116 |
0.342 |
|
| 2020 |
Obinwa U, Pérez A, Lingvay I, Meneghini L, Halm EA, Bowen ME. Multilevel Variation in Diabetes Screening Within an Integrated Health System. Diabetes Care. PMID 32139383 DOI: 10.2337/dc19-1622 |
0.445 |
|
| 2020 |
HARRIS SB, SNOEK FJ, MENEGHINI L, LAUAND F, WESTERBACKA J, DE CLIMENS AR, KHUNTI K. 2192-PUB: Treatment Satisfaction in People with Type 2 Diabetes (T2D) Receiving Basal Insulin (BI): Results from Real-World Studies and Randomized Controlled Trials (RCTs) with Insulin Glargine 300 U/mL (Gla-300) Diabetes. 69: 2192-PUB. DOI: 10.2337/db20-2192-pub |
0.371 |
|
| 2020 |
CHATHA KK, WALSH B, FONTAINE JL, BOWEN ME, MENEGHINI L. 1505-P: Lower Extremity Amputation Trends among People with Diabetes in a Large Urban Environment Diabetes. 69: 1505-P. DOI: 10.2337/db20-1505-p |
0.402 |
|
| 2020 |
MENEGHINI L, CHENG A, EVENOU P, GILL J, MOHAMED A, UMPIERREZ GE. 1038-P: Insulin Glargine 300 U/ml (Gla-300) vs. First-Generation Standard-of-Care Basal Insulin Analogs (SOC-BI) in Insulin-Naïve Patients with Type 2 Diabetes (T2D): Impact of Renal Function on the Outcomes of the Randomized Pragmatic Real-Life Achieve Control S Diabetes. 69: 1038-P. DOI: 10.2337/db20-1038-p |
0.37 |
|
| 2019 |
Meneghini LF, Fortmann AL, Clark TL, Rodriguez K. Making Inroads in Addressing Population Health in Underserved Communities With Type 2 Diabetes. Diabetes Spectrum : a Publication of the American Diabetes Association. 32: 303-311. PMID 31798287 DOI: 10.2337/ds19-0010 |
0.385 |
|
| 2019 |
Meneghini L, Doshi A, Gouet D, Vilsbøll T, Begtrup K, Őrsy P, Ranthe MF, Lingvay I. Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin. Diabetic Medicine : a Journal of the British Diabetic Association. PMID 31705547 DOI: 10.1111/dme.14178 |
0.347 |
|
| 2019 |
Blonde L, Bailey TS, Chao J, Dex TA, Frias JP, Meneghini LF, Roberts M, Aroda VR. Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial. Advances in Therapy. PMID 31359368 DOI: 10.1007/s12325-019-01033-1 |
0.344 |
|
| 2019 |
Zhou FL, Nicholls C, Xie L, Wang Y, Vaidya N, Meneghini LF. Hypoglycaemia and treatment patterns among insulin-treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real-world setting. Endocrinology, Diabetes & Metabolism. 2: e00073. PMID 31294087 DOI: 10.1002/edm2.73 |
0.309 |
|
| 2019 |
Meneghini LF, Mauricio D, Orsi E, Lalic NM, Cali AMG, Westerbacka J, Stella P, Candelas Dea C, Pilorget V, Perfetti R, Khunti K. The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting. Diabetes, Obesity & Metabolism. 21: 1429-1436. PMID 30768845 DOI: 10.1111/dom.13673 |
0.431 |
|
| 2019 |
Pettus J, Roussel R, Liz Zhou F, Bosnyak Z, Westerbacka J, Berria R, Jimenez J, Eliasson B, Hramiak I, Bailey T, Meneghini L. Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study. Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders. PMID 30767173 DOI: 10.1007/s13300-019-0568-8 |
0.334 |
|
| 2019 |
SHAO H, SHI L, FURMAN RE, MENEGHINI L, HARLAN TS, FONSECA V. 174-LB: Impact of Quality Improvement (QI) Program on 5-Year Risk of Diabetes-Related Complications Diabetes. 68: 174-LB. DOI: 10.2337/Db19-174-Lb |
0.303 |
|
| 2019 |
OBINWA UC, LINGVAY I, MENEGHINI L, HALM E, BOWEN ME. 1498-P: Multilevel Variation in Diabetes Screening within an Integrated Health System Diabetes. 68: 1498-P. DOI: 10.2337/DB19-1498-P |
0.346 |
|
| 2019 |
MENEGHINI L, GILL J, DAUCHY A, BACEVICIUS A, STRONG J, BAILEY TS. 1087-P: A Randomized Pragmatic Real-World Clinical Trial Comparing Insulin Glargine 300 U/mL (Gla-300) with Standard of Care First-Generation Basal Insulins (SoC-BIs) in Insulin-Naïve Patients with Type 2 Diabetes: Twelve-Month Analysis of the ACHIEVE Control Study Diabetes. 68: 1087-P. DOI: 10.2337/DB19-1087-P |
0.407 |
|
| 2018 |
Owens DR, Landgraf W, Frier BM, Zhang M, Home PD, Meneghini L, Bolli GB. Commencing insulin glargine 100 U/mL therapy in people with type 2 diabetes: Determinants of achievement of HbA1c goal <7.0. Diabetes, Obesity & Metabolism. PMID 30520217 DOI: 10.1111/dom.13607 |
0.427 |
|
| 2018 |
Heller S, Meneghini L, Nikolajsen A, Kragh N, Lewis HB, Saretsky T, Kosmas CE, Lloyd A. Towards a better understanding of postprandial hyperglycemic episodes in people with diabetes: impact on daily functioning. Current Medical Research and Opinion. 1-19. PMID 30221550 DOI: 10.1080/03007995.2018.1525344 |
0.389 |
|
| 2018 |
Twigg SM, Escalada J, Stella P, Merino-Trigo A, Lavalle-Gonzalez FJ, Cariou B, Meneghini LF. Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-Analysis. Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders. PMID 30203238 DOI: 10.1007/s13300-018-0498-x |
0.409 |
|
| 2018 |
Blonde L, Meneghini L, Peng XV, Boss A, Rhee K, Shaunik A, Kumar S, Balodi S, Brulle-Wohlhueter C, McCrimmon RJ. Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA. Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders. PMID 29600507 DOI: 10.1007/s13300-018-0413-5 |
0.42 |
|
| 2018 |
Meneghini LF, Lee L, Gupta S, Preblick R. The association of hypoglycaemia severity and clinical, patient-reported and economic outcomes in US patients with type 2 diabetes using basal insulin. Diabetes, Obesity & Metabolism. PMID 29316141 DOI: 10.1111/dom.13208 |
0.4 |
|
| 2018 |
MENEGHINI L, ROUSSEL R, ZHOU FL, BOSNYAK Z, WESTERBACKA J, BERRIA R, JIMENEZ J, ELIASSON B, HRAMIAK I, BAILEY TS. Comparable Rates of Severe Hypoglycemia in People with Type 2 Diabetes (T2DM) at High Risk of Hypoglycemia Switching to either Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)—The Lightning Real-World Predictive Modeling Study Diabetes. 67: 97-LB. DOI: 10.2337/DB18-97-LB |
0.359 |
|
| 2018 |
GUNASEKARAN U, FURMAN RE, RODRIGUEZ KM, ELIZABETH OBIALO E, KASSA S, SANTINI NO, FURMAN E, MENEGHINI L. Diabetes Inside—Following the Long-Term Impact of a Diabetes Quality Improvement (QI) Initiative in Primary Care Diabetes. 67: 7-OR. DOI: 10.2337/db18-7-OR |
0.446 |
|
| 2018 |
MCNULTY JN, LEWIS BJ, LA FONTAINE J, ROSE A, GOMEZ M, MENEGHINI L, GUNASEKARAN U, RUIZ MS. Diabetes Foot Wound Healing—A Collaborative Approach Diabetes. 67: 645-P. DOI: 10.2337/DB18-645-P |
0.378 |
|
| 2018 |
PETTUS J, BAILEY TS, ZHOU FL, BOSNYAK Z, WESTERBACKA J, BERRIA R, JIMENEZ J, HRAMIAK I, MENEGHINI L. Similar or Lower Severe Hypoglycemia Rates with Insulin Glargine 300 U/mL (Gla-300) vs. Glargine 100 U/mL (Gla-100), Detemir (IDet), and Insulin Degludec (IDeg) in 112,626 People with Type 2 Diabetes Mellitus (T2DM)—Predictive Modeling Using Real-World Data—Lightning Diabetes. 67: 2289-PUB. DOI: 10.2337/db18-2289-PUB |
0.39 |
|
| 2018 |
PATIL MD, GUNASEKARAN U, FONTAINE JL, MENEGHINI L. Does Improving Glycemic Control Accelerate Healing of Diabetic Foot Ulcers? Diabetes. 67: 2218-PUB. DOI: 10.2337/db18-2218-PUB |
0.388 |
|
| 2018 |
MENEGHINI L, LINJAWI S, SERUSCLAT P, VILSBØLL T, AGNER BF, HANSEN T, LEITER LA. Patients with Type 2 Diabetes (T2D) on the Maximum Dose of Insulin Degludec/Liraglutide (IDegLira) Achieve Glycemic Target—Analyses from the DUAL Program Diabetes. 67: 1109-P. DOI: 10.2337/DB18-1109-P |
0.39 |
|
| 2018 |
BERARD L, MAURICIO D, KHUNTI K, FRANCO DR, WESTERBACKA J, CANDELAS C, PILORGET V, PERFETTI R, MENEGHINI L. Achievement of Individualized HbA1c Targets with Self- vs. Physician-Led Titration of Basal Insulin (BI) in People with Type 2 Diabetes (T2DM), Newly or Recently Initiated on BI—Results from the DUNE Real-World Study Diabetes. 67: 1039-P. DOI: 10.2337/DB18-1039-P |
0.435 |
|
| 2018 |
MAURICIO D, MENEGHINI L, ORSI E, KLIMONTOV V, WESTERBACKA J, MELAS-MELT L, PILORGET V, PERFETTI R, KHUNTI K. Change in Insulin Dose and HbA1c by Geographical Region—Results from the Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) Study Diabetes. 67: 1037-P. DOI: 10.2337/DB18-1037-P |
0.366 |
|
| 2017 |
Zhou FL, Xie L, Pan C, Wang Y, Vaidya N, Ye F, Preblick R, Meneghini L. Relationship between treatment persistence and A1C trends among patients with type 2 diabetes newly initiated on basal insulin. Diabetes, Obesity & Metabolism. PMID 29278460 DOI: 10.1111/dom.13200 |
0.334 |
|
| 2017 |
Tong L, Pan C, Wang H, Bertolini M, Lew E, Meneghini LF. Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: a longitudinal study of a US administrative claims database. Diabetes, Obesity & Metabolism. PMID 29119712 DOI: 10.1111/dom.13156 |
0.341 |
|
| 2017 |
Lingvay I, Chao J, Dalal MR, Meneghini LF. Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures. Diabetes Technology & Therapeutics. PMID 28467113 DOI: 10.1089/dia.2016.0454 |
0.368 |
|
| 2017 |
Mauricio D, Meneghini L, Seufert J, Liao L, Wang H, Tong L, Cali A, Stella P, Carita P, Khunti K. Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes, Obesity & Metabolism. PMID 28251792 DOI: 10.1111/dom.12927 |
0.401 |
|
| 2016 |
Oster G, Sullivan SD, Dalal MR, Kazemi MR, Rojeski M, Wysham CH, Sung J, Johnstone B, Cali AM, Wei LJ, Traylor L, Anhalt H, Hull M, Van Vleet J, Meneghini LF. Achieve Control: A pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes. Postgraduate Medicine. PMID 27690710 DOI: 10.1080/00325481.2016.1241663 |
0.381 |
|
| 2016 |
Meneghini L. New insulin preparations: A primer for the clinician. Cleveland Clinic Journal of Medicine. 83: S27-33. PMID 27176680 DOI: 10.3949/ccjm.83.s1.05 |
0.339 |
|
| 2014 |
DeVries JH, Meneghini L, Barnett AH, Reid T, Dain MP, Landgraf W, Vlajnic A, Traylor L, Bergenstal RM. A Patient-level Analysis of Efficacy and Hypoglycaemia Outcomes Across Treat-to-target Trials with Insulin Glargine Added to Oral Antidiabetes Agents in People with Type 2 Diabetes. European Endocrinology. 10: 23-30. PMID 29872460 DOI: 10.17925/EE.2014.10.01.23 |
0.307 |
|
| 2014 |
Weng J, Retnakaran R, Ariachery C A, Ji L, Meneghini L, Yang W, Woo JT. Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps. Diabetes/Metabolism Research and Reviews. PMID 25196375 DOI: 10.1002/dmrr.2603 |
0.457 |
|
| 2014 |
Brod M, Alolga SL, Meneghini L. Barriers to initiating insulin in type 2 diabetes patients: development of a new patient education tool to address myths, misconceptions and clinical realities. The Patient. 7: 437-50. PMID 24958464 DOI: 10.1007/s40271-014-0068-x |
0.437 |
|
| 2014 |
Ross S, Dzida G, Ji Q, Kaiser M, Ligthelm R, Meneghini L, Nazeri A, Orozco-Beltran D, Pan C, Svendsen AL. Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice. Journal of Diabetes. 6: 243-50. PMID 24103141 DOI: 10.1111/1753-0407.12091 |
0.451 |
|
| 2013 |
Meneghini LF. Intensifying insulin therapy: what options are available to patients with type 2 diabetes? The American Journal of Medicine. 126: S28-37. PMID 23953077 DOI: 10.1016/j.amjmed.2013.06.011 |
0.329 |
|
| 2013 |
Umpierrez GE, Meneghini L. Reshaping diabetes care: the fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 19: 718-28. PMID 23512382 DOI: 10.4158/EP12292.RA |
0.428 |
|
| 2013 |
Meneghini L, Kesavadev J, Demissie M, Nazeri A, Hollander P. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. Diabetes, Obesity & Metabolism. 15: 729-36. PMID 23421331 DOI: 10.1111/dom.12083 |
0.345 |
|
| 2013 |
Caputo S, Andersen H, Kaiser M, Karnieli E, Meneghini LF, Svendsen AL. Effect of baseline glycosylated hemoglobin A1c on glycemic control and diabetes management following initiation of once-daily insulin detemir in real-life clinical practice. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 19: 462-70. PMID 23337147 DOI: 10.4158/EP12269.OR |
0.444 |
|
| 2013 |
Hermanns N, Caputo S, Dzida G, Khunti K, Meneghini LF, Snoek F. Screening, evaluation and management of depression in people with diabetes in primary care. Primary Care Diabetes. 7: 1-10. PMID 23280258 DOI: 10.1016/j.pcd.2012.11.002 |
0.388 |
|
| 2013 |
Freemantle N, Meneghini L, Christensen T, Wolden ML, Jendle J, Ratner R. Insulin degludec improves health-related quality of life (SF-36® ) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials. Diabetic Medicine : a Journal of the British Diabetic Association. 30: 226-32. PMID 23199058 DOI: 10.1111/dme.12086 |
0.353 |
|
| 2013 |
Meneghini LF. Insulin therapy for type 2 diabetes. Endocrine. 43: 529-34. PMID 23104148 DOI: 10.1007/s12020-012-9817-6 |
0.323 |
|
| 2013 |
Meneghini L. Bariatric intervention effective at reversing Type 2 diabetes. Evidence-Based Medicine. 18: 68-9. PMID 22923707 DOI: 10.1136/eb-2012-100834 |
0.335 |
|
| 2013 |
Rana A, Meneghini L, Atkin S, Bain S, Gough S, Raz I, Blonde L, Johansen T, Birkeland K. Insulin degludec given in a flexible once-daily dosing regimen does not compromise efficacy or safety in type 2 diabetes Primary Care Diabetes. 7: 85. DOI: 10.1016/J.PCD.2012.10.073 |
0.348 |
|
| 2013 |
Rodbard HW, Meneghini LF, Russell-Jones DL, Kapur R, Endahl L, Kapor J, Philis-Tsimikas A. Reduced Risk of Hypoglycemia with Insulin Degludec vs. Insulin Glargine in Patients with Type 2 Diabetes and a BMI >30 kg/m2: A Meta-analysis of 5 Randomized Trials Canadian Journal of Diabetes. 37: S56. DOI: 10.1016/J.JCJD.2013.08.166 |
0.346 |
|
| 2013 |
Meneghini LF, Harris S, Evans M, Rasmussen S, Johansen T, Pieber T. Lower Within-Subject Variability in Mean Blood Glucose Concentration with Insulin Degludec vs. Insulin Glargine: A Meta-Analysis of Patients with Type 2 Diabetes Canadian Journal of Diabetes. 37: S26. DOI: 10.1016/J.JCJD.2013.08.079 |
0.35 |
|
| 2012 |
Meneghini LF, Miranda-Palma B. Insulin degludec: a novel ultra-long-acting basal insulin for use in Type 1 and 2 diabetes. Expert Review of Endocrinology & Metabolism. 7: 9-14. PMID 30736105 DOI: 10.1586/eem.11.86 |
0.371 |
|
| 2012 |
Khunti K, Caputo S, Damci T, Dzida GJ, Ji Q, Kaiser M, Karnieli E, Liebl A, Ligthelm RJ, Nazeri A, Orozco-Beltran D, Pan C, Ross SA, Svendsen AL, Vora J, ... ... Meneghini LF, et al. The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries. Diabetes, Obesity & Metabolism. 14: 1129-36. PMID 22830956 DOI: 10.1111/j.1463-1326.2012.01665.x |
0.399 |
|
| 2012 |
Ferroni P, Della-Morte D, Pileggi A, Valente MG, Martini F, Farina FL, Palmirotta R, Meneghini LF, Rundek T, Ricordi C, Guadagni F. Impact of statins on the coagulation status of type 2 diabetes patients evaluated by a novel thrombin-generation assay. Cardiovascular Drugs and Therapy. 26: 301-309. PMID 22527619 DOI: 10.1007/S10557-012-6388-Y |
0.328 |
|
| 2012 |
Khunti K, Damci T, Meneghini L, Pan CY, Yale JF. Study of Once Daily Levemir (SOLVE™): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. Diabetes, Obesity & Metabolism. 14: 654-61. PMID 22443213 DOI: 10.1111/j.1463-1326.2012.01602.x |
0.37 |
|
| 2012 |
Home PD, Meneghini L, Wendisch U, Ratner RE, Johansen T, Christensen TE, Jendle J, Roberts AP, Birkeland KI. Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetes. Diabetic Medicine : a Journal of the British Diabetic Association. 29: 716-20. PMID 22150786 DOI: 10.1111/j.1464-5491.2011.03547.x |
0.434 |
|
| 2012 |
Chollet M, Briggs A, Brin S, Dain MP, Meneghini L, Bergenstal R. PDB43 The Cost of Hypoglycemia in Diabetes: Defining the Severity of the Hypoglycemic Event is Key to Understanding the Economic Burden Value in Health. 15. DOI: 10.1016/J.Jval.2012.03.964 |
0.336 |
|
| 2011 |
Meneghini LF. Insulin for intensifying diabetes treatment. The Journal of Family Practice. 60: S21-8. PMID 21912774 |
0.43 |
|
| 2011 |
Meneghini L, Mersebach H, Kumar S, Svendsen AL, Hermansen K. Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study. Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 17: 727-36. PMID 21550957 DOI: 10.4158/EP10367.OR |
0.402 |
|
| 2011 |
Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA, Lyby K, Jendle JH, Roberts AP, DeVries JH, Meneghini LF. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care. 34: 661-5. PMID 21270174 DOI: 10.2337/dc10-1925 |
0.335 |
|
| 2010 |
Meneghini L, Artola S, Caputo S, Damci T, Dzida G, Kaiser M, Khunti K, Liebl A, Ligthelm R, Maran A, Orozco-Beltran D, Ross S, Yale JF. Practical guidance to insulin management. Primary Care Diabetes. 4: S43-56. PMID 20394891 DOI: 10.1016/S1751-9918(10)60008-3 |
0.384 |
|
| 2010 |
Meneghini L, Liebl A, Abrahamson MJ. Insulin detemir: A historical perspective on a modern basal insulin analogue Primary Care Diabetes. 4. PMID 20394890 DOI: 10.1016/S1751-9918(10)60007-1 |
0.348 |
|
| 2010 |
Meneghini LF, Traylor L, Schwartz SL. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 16: 588-599. PMID 20350924 |
0.363 |
|
| 2010 |
Kennedy L, Solano MP, Meneghini L, Lo M, Cohen MP. Anti-glycation and anti-albuminuric effects of GLY-230 in human diabetes. American Journal of Nephrology. 31: 110-6. PMID 19923796 DOI: 10.1159/000259897 |
0.362 |
|
| 2009 |
Meneghini LF. Perioperative management of diabetes: translating evidence into practice. Cleveland Clinic Journal of Medicine. 76: S53-9. PMID 19880837 DOI: 10.3949/ccjm.76.s4.09 |
0.357 |
|
| 2009 |
Meneghini LF. Early insulin treatment in type 2 diabetes: what are the pros? Diabetes Care. 32: S266-9. PMID 19875562 DOI: 10.2337/dc09-S320 |
0.419 |
|
| 2009 |
Meneghini LF, Dornhorst A, Sreenan S. Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study. Current Medical Research and Opinion. 25: 1029-35. PMID 19281426 DOI: 10.1185/03007990902840871 |
0.385 |
|
| 2008 |
Meneghini LF, Hogan AR, Selvaggi G. Superior mesenteric artery syndrome in type 1 diabetes masquerading as gastroparesis. Diabetes Care. 31: 1983-4. PMID 18628573 DOI: 10.2337/Dc08-0544 |
0.315 |
|
| 2008 |
Dornhorst A, Lüddeke HJ, Sreenan S, Kozlovski P, Hansen JB, Looij BJ, Meneghini L. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. International Journal of Clinical Practice. 62: 659-65. PMID 18324957 DOI: 10.1111/j.1742-1241.2008.01715.x |
0.361 |
|
| 2008 |
Meneghini L. Ethnic disparities in diabetes care: myth or reality? Current Opinion in Endocrinology, Diabetes, and Obesity. 15: 128-34. PMID 18316947 DOI: 10.1097/MED.0b013e3282f5dbb8 |
0.346 |
|
| 2008 |
Selam JL, Koenen C, Weng W, Meneghini L. Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Current Medical Research and Opinion. 24: 11-20. PMID 18021495 DOI: 10.1185/030079908x242755 |
0.421 |
|
| 2008 |
Meneghini LF. Insulin detemir: a long-acting insulin analog for the treatment of Type 1 and 2 diabetes Therapy. 5: 513-529. DOI: 10.2217/14750708.5.4.513 |
0.371 |
|
| 2008 |
Sheikh A, Meneghini L. Update on the Use of Detemir Insulin in the Management of Type 2 Diabetes Us Endocrinology. 4: 38. DOI: 10.17925/use.2008.04.01.38 |
0.399 |
|
| 2007 |
Meneghini L, Kennedy L, Koff R, Kuritzky L, Leal S, Peterson K, Zamudio V. Appropriate advancement of type 2 diabetes therapy. The Journal of Family Practice. 56: 19A-29A; quiz 30A. PMID 17949601 |
0.362 |
|
| 2007 |
Laffel LM, Hsu WC, McGill JB, Meneghini L, Volkening LK. Continued use of an integrated meter with electronic logbook maintains improvements in glycemic control beyond a randomized, controlled trial. Diabetes Technology & Therapeutics. 9: 254-64. PMID 17561796 DOI: 10.1089/dia.2006.0021 |
0.306 |
|
| 2007 |
Meneghini L. Why and how to use insulin therapy earlier in the management of type 2 diabetes. Southern Medical Journal. 100: 164-74. PMID 17330687 DOI: 10.1097/SMJ.0b013e31802ed2ea |
0.359 |
|
| 2006 |
Meneghini L, Hirsch IB. Pharmacotherapies for diabetes management: an update for the practicing clinician. Seminars in Thoracic and Cardiovascular Surgery. 18: 379-89. PMID 17395035 DOI: 10.1053/j.semtcvs.2007.01.003 |
0.373 |
|
| 2005 |
Albisser AM, Alejandro R, Meneghini LF, Ricordi C. How good is your glucose control? Diabetes Technology & Therapeutics. 7: 863-75. PMID 16386092 DOI: 10.1089/dia.2005.7.863 |
0.343 |
|
| 2005 |
Geiger MC, Ferreira JV, Hafiz MM, Froud T, Baidal DA, Meneghini LF, Ricordi C, Alejandro R. Evaluation of metabolic control using a continuous subcutaneous glucose monitoring system in patients with type 1 diabetes mellitus who achieved insulin independence after islet cell transplantation. Cell Transplantation. 14: 77-84. PMID 15881417 |
0.306 |
|
| 2004 |
Ferchak CV, Meneghini LF. Obesity, bariatric surgery and type 2 diabetes--a systematic review. Diabetes/Metabolism Research and Reviews. 20: 438-45. PMID 15386803 DOI: 10.1002/dmrr.507 |
0.387 |
|
| 2004 |
Lewin AJ, Kipnes MS, Meneghini LF, Plotkin DJ, Perevozskaya IT, Shah S, Maccubbin DL, Mitchel YB, Tobert JA. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial. Clinical Therapeutics. 26: 379-89. PMID 15110130 DOI: 10.1016/s0149-2918(04)90033-1 |
0.306 |
|
| 2004 |
Gaudiani L, Lewin A, Meneghini L, Perevozskaya I, Tobert J, Plotkin D, Mitchel Y, Shah S. 1084-169 Efficacy and safety of ezetimibe coadministered with simvastatin versus simvastatin alone in thiazolidinedione-treated patients with type 2 diabetes mellitus Journal of the American College of Cardiology. 43: A479. DOI: 10.1016/S0735-1097(04)92028-1 |
0.37 |
|
| Show low-probability matches. |